About Annexon
Annexon is a publicly listed company based in San Francisco (United States) founded in 2011. Annexon has raised $256 million across 6 funding rounds from investors including Blackstone, BlackRock and Bain Capital. The company has 100 employees. Its website annexonbio.com draws about 10 thousand monthly visits. Annexon offers products and services including ANX005, ANX007, and ANX1502. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is ANNEXON, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Developer of antibodies to treat complement-mediated neurodegenerative diseases. The company is developing the antibody pipeline is based on research involving the classical complement pathway and the role of its initiating molecule, C1q, in the loss of nerve connections and inflammation. It claims to focus on treating diseases such as Alzheimers disease, Huntingtons disease, and other neurodegenerative disorders.
- Headquarters San Francisco, United States
- Employees 100
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website annexonbio.com
- Social LinkedIn X
- Legal Name Annexon, Inc.
- Net Profit-$206.69 M (USD)-49.56as on Dec 31, 2025
- EBITDA-$212.72 M (USD)-41.23as on Dec 31, 2025
- Total Equity Funding$256M (USD)
in 6 rounds
- Latest Funding Round$130.48M (USD), Post-IPO
Jul 2022
- InvestorsBlackstone
& 17 more
- Employee Count100
Products & Services of Annexon
Annexon offers a comprehensive portfolio of products and services, including ANX005, ANX007, and ANX1502.
Antibody for treating Guillain-Barré syndrome by inhibiting C1q.
Inhibitor for eye diseases via intravitreal administration.
Targets C1q for autoimmune diseases in clinical trials.
Funding Insights of Annexon
Annexon has successfully raised a total of $256M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130.48 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $256M
- Total Rounds 6
- Last Round Post-IPO — $130.48M
- First Round $999,999
(Aug 2011)
- Investors Count 18
All 6 funding rounds of Annexon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $130.48M | Post-IPO | – | – | |
| Jul 2020 | $102M | Series D | – | Redmile Group | |
| Dec 2018 | $75M | Series C | – | Bain Capital | |
| Jun 2016 | $44M | Series B | – | New Enterprise Associates | |
| Dec 2014 | $34M | Series A | – | Novartis Venture Fund, Blackstone | – |
| Aug 2011 | $999,999 | Seed | – | – | – |
18 investors in total: 18 institutional.
Investors in Annexon
Annexon has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, BlackRock and Bain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Debt and equity investments are pursued across multiple sectors. | 1984 | baincapital.com | Boston, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland |
Investor details for Annexon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Annexon
73 people are tracked at Annexon (51 in leadership, 12 in board & advisors, 10 in team); the tracked headcount is 100.
| Name | Role | Group |
|---|---|---|
Douglas Love | President & Chief Executive Officer | Leadership |
Michael Overdorf | EVP & Chief Business Officer | Leadership |
Ted Yednock | EVP & Chief Innovation Officer | Leadership |
Jessica Hunt | Field Medical Director | Leadership |
Akbar Khan | Vice President, Global Development Operations | Leadership |
Jeannette Osterloh | Director, Portfolio Strategy & Operations | Leadership |
Bismay Mishra | Senior Director, Commercial Insights | Leadership |
Anton Nguyen | Senior Field Medical Director | Leadership |
Nathalie Bouchard | Vice President Head Of Quality | Leadership |
Violet Torneros | Exec. Director, People | Leadership |
Marta Schumacher | Executive Director, Head Of Global Clinical Operations | Leadership |
Jennifer Lew | EVP & Chief Financial Officer | Leadership |
Peter Collins | Vp, Global Program Team Lead - Neurodegeneration Franchise | Leadership |
Brienna Campbell | Director, Strategic Clinical Outsourcing | Leadership |
Saba Aleem | Senior Vice President Finance | Leadership |
Maya Shamir | Associate Director, Accounting | Leadership |
Harman Hansra | Exec. Director Global Clinical Ops | Leadership |
Lori Taylor | Senior Vice President, Portfolio Strategy And Operations | Leadership |
Behn Sarafpour | Vice President Medical Affairs | Leadership |
Dean Richard Artis | EVP And Chief Scientific Officer | Leadership |
53 more people are available in the full profile.
Complete people profiles for Annexon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Annexon
Annexon is a publicly listed company on the NASDAQ with ticker symbol ANNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jul 2020
- Listed onNASDAQ: ANNX
- Listed entityAnnexon, Inc.
- Exchange sectorHealth technology
- ISINUS03589W1027
- Share price$3.83 (-3.28% on the day) · 2026-10-13
- Market capitalisation$726.1M
- EPS (diluted, trailing year)$-1.15
- Volume (last session)3,421,698
Financials of Annexon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$206.7M | -$212.7M | |
| 2024 | -$138.2M | -$150.6M | |
| 2023 | -$134.2M | -$140.5M | |
| 2022 | -$141.9M | -$142.3M | |
| 2021 | -$130.3M | -$127.3M |
Detailed financial statements for Annexon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Annexon
4 dated milestones of Annexon across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Annexon is founded.
- Funding First funding round of $1,000K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $130.5M.
Competitors of Annexon
Annexon has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Annexon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Annexon
The website of Annexon (annexonbio.com) receives about 10.1K visits a month and ranks #3,104,509 among all websites worldwide, #4,100 in Biotechnology and Pharmaceuticals.
- Monthly visits10.1K
▲ 46.5% vs previous month
- Unique visitors3K
per month
- Global rank#3,104,509
among all websites
- Category rank#4,100
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit9 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Annexon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
alsnewstoday.com | alsnewstoday.com | 100% | #654,643 | – |
Top companies in Oncology
3 companies that operate in the same segment as Annexon (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Annexon
Complete news archive for Annexon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Annexon
Annexon was founded in 2011.
Annexon is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Annexon is a funded company, having raised a total of $256M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1000K, raised on Aug 2011.
Annexon has 100 employees.
Developer of antibodies to treat complement-mediated neurodegenerative diseases. The company is developing the antibody pipeline is based on research involving the classical complement pathway and the role of its initiating molecule, C1q, in the loss of nerve connections and inflammation. It claims to focus on treating diseases such as Alzheimers disease, Huntingtons disease, and other neurodegenerative disorders.
Annexon offers ANX005, ANX007, and ANX1502.
Yes, Annexon is publicly traded on NASDAQ under the ticker symbol ANNX.
Annexon has 18 investors. Key investors include Blackstone, BlackRock, Bain Capital, Citadel, and Janus Henderson Investors.
Annexon operates through Annexon, Inc..